Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

Studied

Randomized trial comparing semaglutide with placebo, both with intensive behavioral therapy and an initial low-calorie diet.

Who / model

611 adults with overweight or obesity and no diabetes, followed for 68 weeks; both groups received 30 counseling visits and an initial 8-week low-calorie diet.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Both primary outcomes favored semaglutide: weight fell 16.0% versus 5.7%, and 86.6% versus 47.6% lost at least 5%. For a secondary outcome, 55.8% versus 13.2% lost at least 15%. Digestive adverse events occurred in 82.8% versus 63.2%; these caused treatment withdrawal in 3.4% versus 0%.

Limits

The authors called for further research to determine whether the findings persist over time.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary